CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.

PubWeight™: 4.36‹?› | Rank: Top 1%

🔗 View Article (PMID 16715087)

Published in Nat Med on May 21, 2006

Authors

Fatima Teixeira-Clerc1, Boris Julien, Pascale Grenard, Jeanne Tran Van Nhieu, Vanessa Deveaux, Liying Li, Valérie Serriere-Lanneau, Catherine Ledent, Ariane Mallat, Sophie Lotersztajn

Author Affiliations

1: INSERM, Unité 581, Hôpital Henri Mondor Créteil, F-9400 France.

Articles citing this

(truncated to the top 100)

Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28

The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80

Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92

Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82

Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94

Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65

Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60

Cannabinoids as novel anti-inflammatory drugs. Future Med Chem (2009) 1.58

Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. Dig Liver Dis (2010) 1.48

Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology (2015) 1.48

Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology (2013) 1.40

Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol (2007) 1.39

Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39

Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2007) 1.34

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther (2007) 1.33

The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol (2007) 1.32

Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol (2008) 1.31

Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30

Endocannabinoids in liver disease. Hepatology (2011) 1.27

Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol (2014) 1.25

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25

Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci (2015) 1.25

CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol (2007) 1.24

Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23

Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol (2007) 1.22

Endocannabinoids and the control of energy homeostasis. J Biol Chem (2008) 1.22

CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res (2009) 1.22

Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21

Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21

CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol (2010) 1.18

AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J (2011) 1.18

Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17

Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol (2008) 1.11

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A (2011) 1.09

Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol (2008) 1.08

Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol (2011) 1.08

The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology (2012) 1.07

Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol (2008) 1.05

Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacol Rev (2010) 1.05

Metabolic effects of chronic cannabis smoking. Diabetes Care (2013) 1.04

Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death Dis (2011) 1.03

The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol (2013) 1.02

Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol (2012) 1.02

Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol (2007) 1.00

The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99

Hepatitis C virus induces the cannabinoid receptor 1. PLoS One (2010) 0.98

Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J Neurotrauma (2013) 0.97

Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol (2010) 0.97

The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem (2007) 0.95

Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95

Macrophage autophagy protects against liver fibrosis in mice. Autophagy (2015) 0.94

The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol (2011) 0.94

Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol (2010) 0.93

Role of cannabinoids in chronic liver diseases. World J Gastroenterol (2008) 0.93

Role of cannabinoids in the development of fatty liver (steatosis). AAPS J (2010) 0.93

Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One (2008) 0.92

Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology (2013) 0.92

Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett (2008) 0.92

Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography. Eur J Nucl Med Mol Imaging (2010) 0.92

Hepatic stellate cells and innate immunity in alcoholic liver disease. World J Gastroenterol (2011) 0.89

Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med (2011) 0.89

Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88

Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis. J Gastroenterol (2010) 0.87

Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoS One (2013) 0.86

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Am J Physiol Endocrinol Metab (2013) 0.86

The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. PLoS One (2010) 0.86

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis (2013) 0.86

Cannabinoid receptor 1 is a major mediator of renal fibrosis. Kidney Int (2015) 0.85

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake. Br J Clin Pharmacol (2014) 0.85

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology (2015) 0.85

Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res (2009) 0.84

Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production. Acta Pharmacol Sin (2010) 0.83

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells. Oncotarget (2015) 0.83

Hepatic stellate cells and astrocytes: Stars of scar formation and tissue repair. Cell Cycle (2011) 0.82

Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function. Front Pharmacol (2014) 0.82

Cannabinoids hurt, heal in cirrhosis. Nat Med (2006) 0.82

Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. Vitam Horm (2009) 0.81

Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice. Br J Pharmacol (2009) 0.81

Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol Int (2008) 0.81

Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. Int Rev Immunol (2014) 0.80

PPAR and liver injury in HIV-infected patients. PPAR Res (2009) 0.80

Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice. PLoS One (2012) 0.80

Extracellular matrix and liver disease. Antioxid Redox Signal (2014) 0.80

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol (2014) 0.79

Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis. Biomed Res Int (2016) 0.78

Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int J Mol Sci (2015) 0.78

Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1. Am J Respir Cell Mol Biol (2015) 0.78

Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls. Int J Endocrinol (2014) 0.78

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Hepatology (2007) 0.78

Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol (2016) 0.77

Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight (2016) 0.77

Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. PLoS One (2009) 0.77

Protective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs. J Pharmacol Exp Ther (2015) 0.77

Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments. Int J Hepatol (2012) 0.77

Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76

Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol (2010) 0.76

Articles by these authors

Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology (2008) 4.46

Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 3.65

Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One (2011) 2.84

Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology (2002) 2.56

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (2005) 2.33

Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature (2005) 2.33

Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci (2005) 2.32

Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg (2009) 2.30

M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology (2013) 2.16

Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14

Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07

Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci (2002) 2.02

Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01

[Assessment of hepatic fibrosis: what is the role of non-invasive markers in 2003?]. Gastroenterol Clin Biol (2003) 1.99

Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology (2007) 1.94

Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain (2010) 1.77

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62

Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. J Hepatol (2010) 1.60

Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol (2005) 1.58

Critical role of amyloid-like oligomers of Drosophila Orb2 in the persistence of memory. Cell (2012) 1.57

Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) (2001) 1.57

Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci (2003) 1.53

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain (2009) 1.50

Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation. Radiology (2012) 1.49

Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology (2008) 1.45

Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44

Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors. Am J Physiol Heart Circ Physiol (2002) 1.43

Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol (2006) 1.43

Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol (2013) 1.42

Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology (2005) 1.41

Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41

Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles. Toxicol Lett (2010) 1.38

Elevated oxidative stress and sensorimotor deficits but normal cognition in mice that cannot synthesize ascorbic acid. J Neurochem (2008) 1.35

CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology (2005) 1.33

Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes (2008) 1.30

Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol (2002) 1.27

Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci (2005) 1.26

GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25

Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology (2004) 1.25

The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J (2007) 1.25

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25

Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25

Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. J Neurosci (2002) 1.22

Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol (2009) 1.21

Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology (2004) 1.21

The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20

The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem (2008) 1.18

Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol (2011) 1.17

Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol (2007) 1.17

Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci (2007) 1.16

Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials (2011) 1.16

Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J (2008) 1.16

Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration. Arch Surg (2007) 1.16

Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13

Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci (2005) 1.13

Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology (2004) 1.12

Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. Stroke (2003) 1.12

The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J (2009) 1.12

Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain (2008) 1.11

A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol (2002) 1.10

Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci (2004) 1.10

The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology (2013) 1.10

Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery. J Mol Cell Cardiol (2008) 1.10

Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol (2010) 1.09

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A (2011) 1.09

Endogenous adenosine increases coronary flow by activation of both A2A and A2B receptors in mice. J Cardiovasc Pharmacol (2003) 1.09

Enhanced airway reactivity and inflammation in A2A adenosine receptor-deficient allergic mice. Am J Physiol Lung Cell Mol Physiol (2007) 1.07

Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol (2008) 1.07

Ascorbate transport by primary cultured neurons and its role in neuronal function and protection against excitotoxicity. J Neurosci Res (2007) 1.07

BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem (2007) 1.07

Involvement of nitric oxide in depolarization-induced suppression of inhibition in hippocampal pyramidal cells during activation of cholinergic receptors. J Neurosci (2007) 1.06

Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology (2003) 1.05